Download PDF
Semin Liver Dis 2021; 41(02): 182-190
DOI: 10.1055/s-0041-1723088
Review Article

Hepatitis B Core-Related Antigen: From Virology to Clinical Application

Hye Won Lee
1   Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2   Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3   Yonsei Liver Center, Severance Hospital, Seoul, Korea
,
Sang Hoon Ahn
1   Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2   Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3   Yonsei Liver Center, Severance Hospital, Seoul, Korea
,
Henry Lik-Yuen Chan
4   Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
5   Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Hepatitis B core-related antigen (HBcrAg) is a composite measure of the serum levels of hepatitis B e antigen, hepatitis B core antigen, and a 22-kDa precore protein. It has been shown to reflect the level and transcriptional activity of covalently closed circular DNA in the liver. Longitudinal cohort studies have improved our understanding of the role of this novel viral marker in the natural history of chronic hepatitis B. HBcrAg kinetics reflect the response to peginterferon, and its role in defining guidelines for stopping peginterferon therapy has been evaluated. HBcrAg is a marker of intrahepatic viral activity, which may influence the risk of hepatocellular carcinoma. In this article, we review the virology and role of HBcrAg in defining phases of chronic hepatitis B. Furthermore, the function of HBcrAg in predicting treatment outcomes and its role in monitoring response to novel antiviral agents will be discussed.

Keywords

hepatitis B virus - hepatocellular carcinoma - cccDNA - antiviral therapy - HBcrAg


Publication History

Article published online:
06 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 2017; 9 (04) E75
    CrossrefPubMedGoogle Scholar
  • 2 Chan HL. JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol 2011; 26 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 3 Kimura T, Ohno N, Terada N. et al. Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005; 280 (23) 21713-21719
    CrossrefPubMedGoogle Scholar
  • 4 Kimura T, Rokuhara A, Sakamoto Y. et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40 (02) 439-445
    CrossrefPubMedGoogle Scholar
  • 5 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther 2018; 47 (01) 43-54
    CrossrefPubMedGoogle Scholar
  • 6 Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel) 2019; 10 (05) E357
    CrossrefPubMedGoogle Scholar
  • 7 van Halewijn GJ, Geurtsvankessel CH, Klaasse J. et al. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol 2019; 114: 1-5
    CrossrefPubMedGoogle Scholar
  • 8 Wong DK, Seto WK, Cheung KS. et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017; 37 (07) 995-1001
    CrossrefPubMedGoogle Scholar
  • 9 Chen EQ, Wang ML, Tao YC. et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat 2019; 26 (05) 586-595
    CrossrefPubMedGoogle Scholar
  • 10 Testoni B, Lebossé F, Scholtes C. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70 (04) 615-625
    CrossrefPubMedGoogle Scholar
  • 11 Honda M, Shirasaki T, Terashima T. et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 2016; 213 (07) 1096-1106
    CrossrefPubMedGoogle Scholar
  • 12 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020; 55 (04) 383-389
    CrossrefPubMedGoogle Scholar
  • 13 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67 (02) 370-398
    CrossrefPubMedGoogle Scholar
  • 14 Kumar M, Sarin SK, Hissar S. et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134 (05) 1376-1384
    CrossrefPubMedGoogle Scholar
  • 15 Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116 (12) 829-834
    CrossrefPubMedGoogle Scholar
  • 16 Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66 (02) 398-411
    CrossrefPubMedGoogle Scholar
  • 17 Seto WK, Wong DK, Fung J. et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 2014; 20 (11) 1173-1180
    Google Scholar
  • 18 Maasoumy B, Wiegand SB, Jaroszewicz J. et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015; 21 (06) 606.e1-606.e10
    Google Scholar
  • 19 Chan HLY, Yasuda S, Wong GLH. et al. Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. J Gastroenterol Hepatol 2020
    Google Scholar
  • 20 Yoshida K, Desbiolles A, Feldman SF. et al. Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2020; ; (epub ahead of print) DOI: 10.1016/j.cgh.2020.04.045.
    CrossrefPubMedGoogle Scholar
  • 21 Loggi E, Vukotic R, Conti F. et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019; 26 (05) 568-575
    CrossrefPubMedGoogle Scholar
  • 22 Chen CJ, Yang HI, Su J. et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 23 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62 (04) 956-967
    CrossrefPubMedGoogle Scholar
  • 24 Tseng TC, Liu CJ, Yang HC. et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142 (05) 1140-1149.e3 , quiz e13–e14
    CrossrefPubMedGoogle Scholar
  • 25 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020; 26 (03) 261-279
    CrossrefPubMedGoogle Scholar
  • 26 Kumada T, Toyoda H, Tada T. et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58 (03) 427-433
    CrossrefPubMedGoogle Scholar
  • 27 Tada T, Kumada T, Toyoda H. et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. J Hepatol 2016; 65 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 28 To WP, Mak LY, Wong DK. et al. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. J Viral Hepat 2019; 26 (12) 1473-1480
    CrossrefPubMedGoogle Scholar
  • 29 Tseng TC, Liu CJ, Hsu CY. et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 2019; 157 (06) 1518-1529.e3
    CrossrefPubMedGoogle Scholar
  • 30 Liaw YF, Sung JJ, Chow WC. et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15) 1521-1531
    CrossrefPubMedGoogle Scholar
  • 31 Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat 2017; 24 (08) 654-661
    CrossrefPubMedGoogle Scholar
  • 32 Hosaka T, Suzuki F, Kobayashi M. et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 2019; 49 (04) 457-471
    CrossrefPubMedGoogle Scholar
  • 33 Hosaka T, Suzuki F, Kobayashi M. et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30 (10) 1461-1470
    CrossrefPubMedGoogle Scholar
  • 34 Chen S, Jia J, Gao Y. et al. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients. Clin Chim Acta 2018; 486: 237-244
    CrossrefPubMedGoogle Scholar
  • 35 Yasunaka T, Takaki A, Yagi T. et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int 2011; 5 (04) 918-926
    CrossrefPubMedGoogle Scholar
  • 36 Yu J, Ye Y, Liu J. et al. The role of hepatitis B core-related antigen in predicting hepatitis B virus recurrence after liver transplantation. Aliment Pharmacol Ther 2019; 50 (09) 1025-1036
    CrossrefPubMedGoogle Scholar
  • 37 Riveiro-Barciela M, Bes M, Rodríguez-Frías F. et al. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin Microbiol Infect 2017; 23 (11) 860-867
    Google Scholar
  • 38 Chuaypen N, Posuwan N, Payungporn S. et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016; 36 (06) 827-836
    CrossrefPubMedGoogle Scholar
  • 39 van Campenhout MJH, Rijckborst V, Brouwer WP. et al. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Viral Hepat 2019; 26 (10) 1156-1163
    CrossrefPubMedGoogle Scholar
  • 40 Chuaypen N, Posuwan N, Chittmittraprap S. et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect 2018; 24 (03) 306.e7-306.e13
    CrossrefPubMedGoogle Scholar
  • 41 Lai CL, Wong D, Ip P. et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 2017; 66 (02) 275-281
    CrossrefPubMedGoogle Scholar
  • 42 Lutgehetmann M, Volzt T, Quaas A. et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13 (01) 57-66
    CrossrefPubMedGoogle Scholar
  • 43 Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45 (12) 3942-3947
    CrossrefPubMedGoogle Scholar
  • 44 Rokuhara A, Sun X, Tanaka E. et al. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J Gastroenterol Hepatol 2005; 20 (11) 1726-1730
    CrossrefPubMedGoogle Scholar
  • 45 Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. J Viral Hepat 2018; 25 (08) 886-893
    CrossrefPubMedGoogle Scholar
  • 46 Sonneveld MJ, van Oord GW, van Campenhout MJ. et al. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat 2019; 26 (07) 828-834
    CrossrefPubMedGoogle Scholar
  • 47 Kho-Herman SGR, Chan HL-Y. Stopping nucleos (t) ide analog treatment in chronic hepatitis B—Who and when?. Liver Research 2017; 1 (02) 135-139
    CrossrefPubMedGoogle Scholar
  • 48 van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018; 38 (Suppl. 01) 90-96
    CrossrefPubMedGoogle Scholar
  • 49 Matsumoto A, Tanaka E, Minami M. et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37 (08) 661-666
    CrossrefPubMedGoogle Scholar
  • 50 Tanaka A. Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res 2020; 50 (08) 892-923
    CrossrefPubMedGoogle Scholar
  • 51 Jung KS, Park JY, Chon YE. et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016; 51 (08) 830-839
    CrossrefPubMedGoogle Scholar
  • 52 Tseng TN, Hu TH, Wang JH. et al. Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU/mL. Clin Gastroenterol Hepatol 2020; ; (epub ahead of print) DOI: 10.1016/j.cgh.2020.04.037.
    CrossrefPubMedGoogle Scholar
  • 53 Fan R, Peng J, Xie Q. et al. Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients. J Infect Dis 2020; 222 (04) 611-618
    CrossrefPubMedGoogle Scholar
  • 54 Hsu YC, Nguyen MH, Mo LR. et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther 2019; 49 (01) 107-115
    CrossrefPubMedGoogle Scholar
  • 55 Papatheodoridi M, Hadziyannis E, Berby F. et al. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat 2020; 27 (02) 118-126
    CrossrefPubMedGoogle Scholar
  • 56 Seto WK, Wong DK, Chan TS. et al. Association of hepatitis B core-related antigen with hepatitis b virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016; 111 (12) 1788-1795
    CrossrefPubMedGoogle Scholar
  • 57 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 2017; 66 (04) 1296-1313
    CrossrefPubMedGoogle Scholar
  • 58 Agarwal K, Gane E, Cheng W. et al. HBcrAg, HBV-RNA declines in a phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-positive and negative virally suppressed subjects with hepatitis B. Hepatology 2017;66(1, Suppl)
    Google Scholar
  • 59 Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol 2016; 22 (37) 8314-8321
    CrossrefPubMedGoogle Scholar
  • 60 Suzuki Y, Maekawa S, Komatsu N. et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res 2019; 49 (01) 51-63
    CrossrefPubMedGoogle Scholar